Ketamine clinics carry more regulatory weight than a typical medspa. Ketamine is a Schedule III controlled substance, and most states tie every dose, chart, and good faith exam to a licensed physician's signature. This guide covers what a medical director for ketamine clinics actually needs to cover in 2026, and where clinics get the arrangement wrong.
- A medical director for ketamine clinics has to sign off on Schedule III prescribing, not just aesthetic procedures — treat it as controlled-substance oversight, not a medspa add-on.
- Chart review cadence matters more here than in Botox clinics; many states set the threshold at 10% of encounters, not an annual glance.
- Physician availability inside 24 hours beats a cheaper contract with a five-day response window — dosing complications don’t wait.
- IV hydration and hormone therapy oversight models are the closest analogs — borrow their structure, not their controlled-substance leniency.
- Any arrangement where the physician has never reviewed a ketamine-specific protocol before signing is a Skip.
Why this matters
A nurse-led medspa running Botox and filler can get away with a collaborating physician who signs paperwork once a quarter. A ketamine clinic can't. Ketamine is a Schedule III controlled substance under federal law, which means the physician attached to your clinic is on record for every prescription, every dosing decision, and every adverse event report filed with the state board.
Most states that allow nurse practitioners or non-physician providers to run ketamine programs require a collaborating physician or medical director relationship specific to controlled substance administration — separate from, and often stricter than, the aesthetics supervision rules that govern injectables. Get this wrong and the exposure isn't a warning letter. It's a DEA or state medical board inquiry with your clinic's name on it.
Who this is for
This applies to NP-owned and nurse-led ketamine infusion or IM injection clinics treating depression, anxiety, or chronic pain, standalone ketamine clinics adding infusion services to an existing medical director for ketamine clinics roster, and medspas layering ketamine onto a Botox and filler book of business. If your clinic dispenses or administers a Schedule III substance without a physician actively reviewing charts, you're operating outside the model regulators expect in 2026, regardless of how the paperwork reads.
What to look for in a medical director for ketamine clinics
Comfort with controlled substance authority
A physician who's never handled Schedule III prescribing shouldn't be your first call. Ask directly whether they hold an active DEA registration and have signed off on controlled substance protocols before — not just aesthetic device consent forms. This single question filters out most generalist medspa physicians fast.
State-specific collaborating physician requirements
Requirements vary sharply by state — chart review percentage, on-site visit frequency, and whether telehealth oversight counts. A medical director who can name your state's specific collaborating physician statute for controlled substances, not just aesthetics, is doing the job correctly.
Chart review cadence and documentation
Many states set the review threshold at 10% of patient charts monthly for controlled substance clinics — higher than the light-touch review common in cosmetic-only practices. Documentation needs to show dates, findings, and physician signature, not a rubber stamp. Review how chart reviews get documented for medical director compliance before you sign anything.
Good faith exam rigor for a controlled substance
The initial evaluation before a patient's first ketamine session carries more weight than a pre-Botox consult. It has to screen for contraindications specific to dissociative anesthetics — cardiovascular history, psychiatric history, current medications — not a generic intake form repurposed from filler patients.
Emergency availability and response protocol
Ketamine sessions involve dissociation, blood pressure changes, and occasional adverse reactions during the 40-60 minute infusion window. A medical director who can't guarantee availability inside 24 hours for a clinical question isn't structured for this service line, no matter how competitive the monthly fee looks.
Top picks: oversight models for ketamine clinics
The infusion-clinic analog — Consider. IV hydration businesses face a similar structure: a licensed provider administering something intravenously under a supervising physician, with documentation tied to each session. The oversight framework used for medical director services for IV hydration clinics transfers well, but ketamine's Schedule III status means the chart review and prescribing oversight need to go further than a hydration protocol requires. Verdict: Consider as a structural template, not a drop-in solution.
The controlled-substance comparison — Consider. Hormone therapy clinics deal with prescription-only substances under a collaborating physician model that mirrors ketamine's regulatory burden more closely than aesthetics does. The framework used for medical director oversight in hormone therapy clinics is a reasonable reference point for structuring prescribing authority, refill protocols, and adverse event reporting. Verdict: Consider — closest regulatory match available.
The dedicated ketamine-specific arrangement — Buy. A physician who has explicitly reviewed and signed off on ketamine protocols, understands the Schedule III documentation burden, and commits to a chart review cadence matched to your state's requirement is the arrangement that holds up in an audit. Verdict: Buy — this is the baseline, not a premium tier.
The generalist medspa physician with no controlled-substance history — Skip. A collaborating physician who signs Botox and filler paperwork but has never touched a DEA-registered protocol is a liability dressed up as a cost-saving move. Verdict: Skip.
“If your collaborating physician hasn’t reviewed a ketamine chart in 30 days, you don’t have oversight — you have paperwork.”
What to avoid
- A collaborating physician agreement copied from a Botox clinic template. Controlled substance clinics need language specific to Schedule III prescribing, refill authority, and adverse event escalation — a generic aesthetics agreement won't hold up.
- A medical director who reviews charts quarterly. Ketamine's dosing risk profile and controlled substance status call for a monthly cadence in most states, not an annual sign-off.
- A telehealth-only oversight model for in-person IV sessions. Telehealth collaborating physician structures work for consult-based programs, but a physician who has never been on-site or reachable during an active infusion session is the wrong fit for IV or IM administration.
Verdict comparison
| Criterion | Generalist medspa physician | Ketamine-specific medical director |
|---|---|---|
| DEA / controlled substance comfort | Rarely verified | Confirmed before contract signed |
| Chart review cadence | Quarterly or annual | Monthly, often 10% threshold |
| Response window | Days | Inside 24 hours |
| Good faith exam scope | Generic aesthetics intake | Dissociative-anesthetic screening |
| Verdict | Skip | Buy |
Get physician oversight structured correctly
Talk through chart review, good faith exams, and collaborating physician terms for your clinic.
FAQ
Does a ketamine clinic need a medical director in 2026?
Most states require a licensed collaborating physician or medical director for any clinic administering ketamine, since it’s a Schedule III controlled substance. The specific requirement — chart review percentage, on-site visits, prescribing authority — varies by state in 2026.
What’s the difference between a medical director and a collaborating physician for ketamine clinics?
A medical director typically oversees clinic-wide protocols and staff training, while a collaborating physician signs off on individual provider scope of practice. Ketamine clinics often need both roles covered, sometimes by the same physician depending on state law.
How often should charts be reviewed at a ketamine clinic?
Many states set the review threshold at 10% of patient charts monthly for controlled substance clinics, higher than the light-touch review common in cosmetic-only practices. Confirm your specific state’s requirement before finalizing an agreement.
Can a telehealth physician oversee an in-person ketamine clinic?
Telehealth oversight works for consult-heavy programs but is a poor fit for in-person IV or IM administration, where physician availability inside 24 hours matters during active sessions. In-person or hybrid oversight is the safer structure for infusion clinics.
Is ketamine oversight the same as Botox or filler supervision?
No. Ketamine’s Schedule III status means the collaborating physician relationship carries controlled substance prescribing and documentation obligations that aesthetics-only supervision doesn’t require. Treat ketamine oversight as its own compliance category.
What happens if a ketamine clinic operates without proper physician oversight?
Operating without the required collaborating physician or medical director exposes the clinic to state medical board action and, given ketamine’s controlled substance status, potential DEA scrutiny. This risk is higher than for non-controlled aesthetic services.
How fast should a medical director respond to a ketamine clinic’s clinical question?
Inside 24 hours is the standard expectation for controlled substance clinics, given the dosing and adverse-reaction risks during a 40-60 minute infusion session. A slower response window signals the arrangement isn’t structured for this service line.
Do good faith exams differ for ketamine patients versus Botox patients?
Yes. A good faith exam before a first ketamine session needs to screen for cardiovascular and psychiatric contraindications specific to dissociative anesthetics, not a generic aesthetics intake form.
One last thing
The clinics that get flagged in 2026 rarely get flagged for the ketamine itself — they get flagged for a chart review file that shows no signature in 90 days. If your medical director for ketamine clinics can't produce a dated, signed chart review inside the last month, that's the gap to fix before anything else.
Related guides
